English 中文版
Clinical Center
Medical Oncology
Gynecologic Oncology
Traditional Chinese Medicine/Integrative Oncology
Radiation Oncology
Medical Laboratory

Contact Us

Tel: +86-731-88651900

Fax: +86-731-88651999

Mail: hnszlyy_network@163.com

Add: 283 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, P.R. China

Home > News > Newsroom

【2019 ASCCP】Professor Wang Jing from Hunan Cancer Hospital gave oral reports on new method for cervical cancer detection in ASCCP conference.

39Admin2019-07-03from:Hunan Cancer Hospital

On April 4-7, 2019, the annual meeting of American Aociety for Colposcopy and cervical Pathology (ASCCP) was held in Atlanta. Founded in 1964, ASCCP is a non-profit professional society and an authoritative organization in the world for cervical lesions. In each year’s annual meeting of ASCCP, medical professionals from all over the world discuss colposcopy, cervical cancer, HPV and other sexually transmitted diseases, and vulvar diseases. On April 5th, Professor Wang Jing from Hunan Cancer Hospital appeared at the ASCCP conference and gave her oral speech with new research. Tumor Information made a brief introduction for the study and invited Professor Wang Jing to comment.

Research Purposes

The aim of this study is to evaluate the clinical value of the SOX1 methylation (SOX1m) gene for cervical adenocarcinoma.

Research Method

The methylation status of SOX1 was assessed by methylation-specific polymerase chain reaction. The chi-square test was used to compare the SOX1m status in patients with cervical adenocarcinoma and normal cervical disease. Kaplan-Meier method was used to estimate and compare the total survival time and disease-free survival rate. The Cox regression model was used to assess the prognostic significance of SOX1m in patients with cervical adenocarcinoma. The sensitivity and specificity of DNA methylation levels were also analyzed.

Research Results

A total of 166 patients with cervical adenocarcinoma and 25 normal controls were enrolled. The results showed that the level of SOX1m was significantly higher in the cervical adenocarcinoma group compared with control group. The sensitivity and specificity of SOX1m for detecting cervical adenocarcinoma were 87.22% and 70.37%, respectively. The total survival time of SOX1m positive group was significantly longer than that of PAX1m negative group.

Research Conclusion

The results indicate that SOX1 methylation is expected to be a biomarker for detection and prognosis  monitoring of cervical adenocarcinoma.

Comment from Professor Wang Jing

Cervical cancer ranks fourth among the common malignant tumors in women worldwide. The number of

patients with cervical cancers in developing countries accounts for 85% of the world's total, and it is also one of the leading causes of death. In recent years, the incidence and mortality of cervical squamous cell carcinoma have gradually declined due to effective screening. However, in the past 30 years, the incidence of cervical adenocarcinoma has increased year by year, accounting for about 20% of the total number of cervical cancers. About 2/3 (60.3%) patients with cervical adenocarcinoma are younger than 50 years old, and more than half (57.38%) of them are younger than 40 years old. The possible reason is that cervical adenocarcinoma is difficult to find in the early stage of carcinomatous change, and the existing screening methods such as cytological screening are less sensitive, which make it difficult for early diagnosis. Currently, the treatment of cervical adenocarcinoma and adenosquamous carcinoma is similar to cervical squamous carcinoma, but they are relatively less sensitive to chemotherapy and radiotherapy and have a poor prognosis, when compared with squamous carcinoma at the same stage. This is because their etiology, tissue type and biological behavior are different from that of squamous carcinoma. Therefore, searching for new molecular biomarkers and combining cytologic examination and human papillomavirus (HPV) detection to improve the sensitivity and specificity of early diagnosis for cervical adenocarcinoma is the focus of clinical research.

Under the support of project planning of National Natural Science Foundation of China, Natural Science Foundation of Hunan Province and Hunan Clinical Research Center for Gynecological Oncology, Professor Wang Jing’s team from Hunan Cancer Hospital conducted the study in order to solve the current difficulty in early screening and early diagnosis of cervical adenocarcinoma, and problem of lacking monitoring marker for follow-up and prognosis. The finding of molecular biomarkers such as SOX1 and ZNF582 gene methylation is expected to improve the sensitivity and specificity of early screening for cervical adenocarcinoma. It is expected to be a breakthrough in early screening difficulties and helpful for prognosis monitoring of patients, and can provide predicted evidence in sensitivity and efficacy of chemoradiotherapy.

Clinical Service
Find a Doctor
Request an Appointment
Research & Education
Cancer Research
Clinical Trials
Selected Publications
Graduate Education
Resident Training
Download Center
About us